Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero

Novartis’ former CEO Joe Jimenez and NIBR head Mark Fishman believe that pairing digital technology with drug development in large underserved indications can provide a solid investment model and expedite the creation of medicines in disease areas that have been all but abandoned by their former peer pharma companies.

Together with co-founder Paul Sekhri, president and CEO of eGenesis Inc., they created investment firm Aditum Bio in 2019. Sekhri — a veteran executive of Novartis AG (NYSE:NVS; SIX:NOVN) himself  — is remaining at eGenesis. 

Jimenez led Novartis from 2010 until January 2018. Fishman was the founding president of the Novartis Institutes of BioMedical Research from from 2002-16.  At Aditum, Jimenez is co-founder and managing director, and Fishman is co-founder and chair of the SAB.